Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Barata

Showing results (161-170 of 203) with videos related to

Pageof 21
Sort By:
The Oncologist|March 11, 2022
Multi-institutional Analysis of the Clinical and Genomic Characteristics of Black Patients with Metastatic Hormone-Sensitive Prostate CancerMeredith N Freeman, Albert Jang, Jason Zhu, et al.
Journal for Immunotherapy of Cancer|March 23, 2026
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of renal cell carcinoma, version 3.0Rana R McKay, Archana Ajmera, Michael B Atkins, et al.
Kidney Cancer (Clifton, Va.)|July 1, 2025
Durable responses to immune checkpoint inhibitor-based regimens for metastatic clear cell renal cell carcinoma stratified by IMDC risk groups: A pooled analysis of four randomized phase 3 trialsAlbert Jang, Jeffrey Y Zhong, Hamsa L S Kumar, et al.
The Oncologist|August 29, 2022
Comprehensive Genomic Profiling of Cell-Free DNA in Men With Advanced Prostate Cancer: Differences in Genomic Landscape Based on RaceRaquel Zimmerman, Mehmet A Bilen, Elisabeth I Heath, et al.
Clinical Genitourinary Cancer|January 13, 2026
Non-Immunotherapy Arm Allocations in Phase 3 Genitourinary Cancer Trials with ImmunotherapyAbby L Grier, Albert Jang, Jeffrey Y Zhong, et al.
International Journal of Molecular Sciences|June 26, 2025
<i>HSD3B1</i> (c.1100C) Genotype Is Associated with Distinct Tumoral and Clinical Outcomes in Breast and Endometrial CancersNikitha Vobugari, Allison Makovec, Samuel Kellen, et al.
Targeted Oncology|September 30, 2018
Immunological Correlates of Response to Immune Checkpoint Inhibitors in Metastatic Urothelial CarcinomaAlice Tzeng, C Marcela Diaz-Montero, Patricia A Rayman, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 16, 2021
Randomized Phase II Trial of Sipuleucel-T with or without Radium-223 in Men with Bone-metastatic Castration-resistant Prostate CancerCatherine H Marshall, Wei Fu, Hao Wang, et al.
JAMA Network Open|August 20, 2025
Statin Use in Patients With Advanced Prostate Cancer in the TITAN and SPARTAN TrialsSoumyajit Roy, Zeynep Irem Ozay, Avirup Guha, et al.
The Prostate|April 28, 2023
Comparison of circulating tumor DNA between African American and Caucasian patients with metastatic castrate-resistant prostate cancer post-abiraterone and/or enzalutamideAlbert Jang, Sree M Lanka, Minqi Huang, et al.
Pageof 21

Showing results (161-170 of 203) with videos related to

Sort By:
Pageof 21
The Oncologist|March 11, 2022
Multi-institutional Analysis of the Clinical and Genomic Characteristics of Black Patients with Metastatic Hormone-Sensitive Prostate CancerMeredith N Freeman, Albert Jang, Jason Zhu, et al.
Journal for Immunotherapy of Cancer|March 23, 2026
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of renal cell carcinoma, version 3.0Rana R McKay, Archana Ajmera, Michael B Atkins, et al.
Kidney Cancer (Clifton, Va.)|July 1, 2025
Durable responses to immune checkpoint inhibitor-based regimens for metastatic clear cell renal cell carcinoma stratified by IMDC risk groups: A pooled analysis of four randomized phase 3 trialsAlbert Jang, Jeffrey Y Zhong, Hamsa L S Kumar, et al.
The Oncologist|August 29, 2022
Comprehensive Genomic Profiling of Cell-Free DNA in Men With Advanced Prostate Cancer: Differences in Genomic Landscape Based on RaceRaquel Zimmerman, Mehmet A Bilen, Elisabeth I Heath, et al.
Clinical Genitourinary Cancer|January 13, 2026
Non-Immunotherapy Arm Allocations in Phase 3 Genitourinary Cancer Trials with ImmunotherapyAbby L Grier, Albert Jang, Jeffrey Y Zhong, et al.
International Journal of Molecular Sciences|June 26, 2025
<i>HSD3B1</i> (c.1100C) Genotype Is Associated with Distinct Tumoral and Clinical Outcomes in Breast and Endometrial CancersNikitha Vobugari, Allison Makovec, Samuel Kellen, et al.
Targeted Oncology|September 30, 2018
Immunological Correlates of Response to Immune Checkpoint Inhibitors in Metastatic Urothelial CarcinomaAlice Tzeng, C Marcela Diaz-Montero, Patricia A Rayman, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 16, 2021
Randomized Phase II Trial of Sipuleucel-T with or without Radium-223 in Men with Bone-metastatic Castration-resistant Prostate CancerCatherine H Marshall, Wei Fu, Hao Wang, et al.
JAMA Network Open|August 20, 2025
Statin Use in Patients With Advanced Prostate Cancer in the TITAN and SPARTAN TrialsSoumyajit Roy, Zeynep Irem Ozay, Avirup Guha, et al.
The Prostate|April 28, 2023
Comparison of circulating tumor DNA between African American and Caucasian patients with metastatic castrate-resistant prostate cancer post-abiraterone and/or enzalutamideAlbert Jang, Sree M Lanka, Minqi Huang, et al.
Pageof 21